Key result
Novel therapeutic approaches targeting defective calcium release via cardiac ryanodine receptors are currently being evaluated for arrhythmias in heart failure and CPVT.
This review highlights the potential of targeting cardiac ryanodine receptors (RyR2) to correct defective calcium release and treat arrhythmias in heart failure and CPVT.
Answers are grounded in this paper and cite their sources.
RyR2 leak drives arrhythmias in HF and CPVT; leaves open whether targeted stabilization improves clinical outcomes.
Cardiac arrhythmia is an important cause of death in patients with heart failure (HF) and inherited arrhythmia syndromes, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Alterations in intracellular calcium handling play a prominent role in the generation of arrhythmias in the failing heart. Diastolic calcium leak from the sarcoplasmic reticulum (SR) via cardiac ryanodine receptors (RyR2) may initiate delayed afterdepolarizations and triggered activity leading to arrhythmias. Similarly, SR Ca(2+) leak through mutant RyR2 channels may cause triggered activity during exercise in patients with CPVT. Novel therapeutic approaches, based on recent advances in the understanding of the cellular mechanisms underlying arrhythmias in HF and CPVT, are currently being evaluated to specifically correct defective Ca(2+) release in these lethal syndromes.
No takes yet. Share an insight, caveat, or question.
Wehrens et al. (2005) conducted a review in Heart failure and inherited arrhythmia syndromes (e.g., CPVT). Ryanodine Receptor-Targeted Anti-Arrhythmic Therapy was evaluated. Novel therapeutic approaches targeting defective calcium release via cardiac ryanodine receptors are currently being evaluated for arrhythmias in heart failure and CPVT.
Synapse has enriched 10 related papers. Consider them for comparative context: